SDGR logo

Schrödinger (SDGR) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

06 February 2020

Indexes:

Not included

Description:

Schrodinger, Inc. is an American biotechnology company specializing in software for the discovery and research of new drugs. Founded in 1990, the company is headquartered in New York. Schrodinger has developed a computational platform that can predict critical properties of molecules with a high degree of accuracy. This key capability allows drug development teams to design and selectively synthesize molecules with more optimal properties, reducing on average the time and costs required to identify a development candidate, and increasing the likelihood that a drug discovery program will enter clinical development.

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Feb 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

13 Nov '24 BMO Capital
Outperform
17 Oct '24 BMO Capital
Outperform
21 Aug '24 Morgan Stanley
Equal-Weight
11 July '24 Keybanc
Overweight
02 July '24 Leerink Partners
Outperform
02 May '24 Craig-Hallum
Buy
02 May '24 Citigroup
Buy
01 Mar '24 Goldman Sachs
Neutral
01 Mar '24 Citigroup
Buy
29 Feb '24 Piper Sandler
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Schrodinger, Inc. (SDGR) Reports Q3 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) Reports Q3 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) Reports Q3 Loss, Misses Revenue Estimates
SDGR
zacks.com12 November 2024

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.86 per share a year ago.

Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium
Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium
Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium
SDGR
businesswire.com23 October 2024

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) today announced new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, during a poster session at the 36th EORTC-NCI-AACR Symposium (ENA 2024). The data demonstrate that in preclinical models, treatment with SGR-3515 results in synergistic anti-tumor activity that leads to deeper and more durable responses compared to inhibitors that target only Wee1 or Myt1. The preclinical data also show that SGR-3515 has a favorable ph.

Kuehn Law Encourages Investors of Schrodinger, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Schrodinger, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Schrodinger, Inc. to Contact Law Firm
SDGR
prnewswire.com19 September 2024

NEW YORK , Sept. 19, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Schrodinger, Inc. (NASDAQ: SDGR) breached their fiduciary duties to shareholders.

Schrödinger, Inc. (SDGR) Q2 2024 Earnings Call Transcript
Schrödinger, Inc. (SDGR) Q2 2024 Earnings Call Transcript
Schrödinger, Inc. (SDGR) Q2 2024 Earnings Call Transcript
SDGR
seekingalpha.com01 August 2024

Schrödinger, Inc. (NASDAQ:SDGR ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations & Corporate Communications Ramy Farid - President & Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President R&D, Therapeutics Conference Call Participants Michael Yee - Jefferies Scott Schoenhaus - KeyBanc Conor McKay - BMO Capital Markets David Leibowitz - Citi Matt Hewitt - Craig-Hallam Capital Chris Shibutani - Goldman Sachs Steven Mah - TD Cowen Operator Thank you for standing by. Welcome to Schrödinger's Conference Call to review our Second Quarter 2024 Financial Results.

Schrodinger, Inc. (SDGR) Reports Q2 Loss, Tops Revenue Estimates
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Tops Revenue Estimates
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Tops Revenue Estimates
SDGR
zacks.com31 July 2024

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.21 per share a year ago.

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SDGR
businesswire.com14 June 2024

NEW YORK--(BUSINESS WIRE)--Schrödinger today reported that on June 11, 2024, the company granted (i) a non-statutory stock option and (ii) restricted stock units (RSUs).

Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates
SDGR
Zacks Investment Research01 May 2024

Schrodinger, Inc. reported a quarterly loss of $0.76 per share, matching the Zacks Consensus Estimate. This is compared to a loss of $0.38 per share in the same quarter last year.

Schrödinger to Announce First Quarter 2024 Financial Results on May 1
Schrödinger to Announce First Quarter 2024 Financial Results on May 1
Schrödinger to Announce First Quarter 2024 Financial Results on May 1
SDGR
Business Wire10 April 2024

Schrödinger is set to announce its financial results for the first quarter of 2024 on May 1, 2024, after the close of the financial markets.

Schrodinger, Inc. (SDGR) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Schrodinger, Inc. (SDGR) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Schrodinger, Inc. (SDGR) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
SDGR
Zacks Investment Research28 February 2024

While the top- and bottom-line numbers for Schrodinger, Inc. (SDGR) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Schrodinger, Inc. (SDGR) Reports Q4 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Misses Revenue Estimates
SDGR
Zacks Investment Research28 February 2024

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.39 per share a year ago.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the primary business of Schrödinger?
  • What is the ticker symbol for Schrödinger?
  • Does Schrödinger pay dividends?
  • What sector is Schrödinger in?
  • What industry is Schrödinger in?
  • What country is Schrödinger based in?
  • When did Schrödinger go public?
  • Is Schrödinger in the S&P 500?
  • Is Schrödinger in the NASDAQ 100?
  • Is Schrödinger in the Dow Jones?
  • When was Schrödinger's last earnings report?
  • When does Schrödinger report earnings?
  • Should I buy Schrödinger stock now?

What is the primary business of Schrödinger?

Schrodinger, Inc. is an American biotechnology company specializing in software for the discovery and research of new drugs. Founded in 1990, the company is headquartered in New York. Schrodinger has developed a computational platform that can predict critical properties of molecules with a high degree of accuracy. This key capability allows drug development teams to design and selectively synthesize molecules with more optimal properties, reducing on average the time and costs required to identify a development candidate, and increasing the likelihood that a drug discovery program will enter clinical development.

What is the ticker symbol for Schrödinger?

The ticker symbol for Schrödinger is NASDAQ:SDGR

Does Schrödinger pay dividends?

No, Schrödinger does not pay dividends

What sector is Schrödinger in?

Schrödinger is in the Healthcare sector

What industry is Schrödinger in?

Schrödinger is in the Health Information Services industry

What country is Schrödinger based in?

Schrödinger is headquartered in United States

When did Schrödinger go public?

Schrödinger's initial public offering (IPO) was on 06 February 2020

Is Schrödinger in the S&P 500?

No, Schrödinger is not included in the S&P 500 index

Is Schrödinger in the NASDAQ 100?

No, Schrödinger is not included in the NASDAQ 100 index

Is Schrödinger in the Dow Jones?

No, Schrödinger is not included in the Dow Jones index

When was Schrödinger's last earnings report?

Schrödinger's most recent earnings report was on 12 November 2024

When does Schrödinger report earnings?

The next expected earnings date for Schrödinger is 28 February 2025

Should I buy Schrödinger stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions